share_log

Goldman Sachs Initiates Coverage On Olema Pharmaceuticals With Buy Rating, Announces Price Target of $24

Moomoo 24/7 ·  Apr 2 07:09

Goldman Sachs analyst Richard Law initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Price Target of $24.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment